Immunicum, PCI Biotech extend alliance on novel cancer vaccines
Immunicum and PCI Biotech will jointly research introducing tumor-independent immune targets into the tumor microenvironment with vaccination or adoptive immunotherapies as a possibility of overcoming current hurdles in cancer immunotherapy. Read More
Northwest Biotherapeutics receives $15M in financing
Northwest Biotherapeutics, a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, has secured $15 million in financing to accelerate its brain cancer program. Read More
Bone Therapeutics, Link Health enter agreement for rights of ALLOB
Bone Therapeutics and Link Health Pharma have signed a nonbinding agreement for the global rights regarding the development, manufacturing, and commercialization of ALLOB, Bone Therapeutics' off-the-shelf, human, allogeneic bone cell therapy derived from bone marrow mesenchymal stromal cells. The two companies plan to sign a binding license agreement by the end of 2021. Read More
Ranok Therapeutics, Pfizer team up on targeted protein degradation
Ranok Therapeutics and Pfizer are teaming up to evaluate Ranok's chaperone-mediated protein degradation platform technology on an undisclosed cancer target. Read More
Codex DNA, TriLink Biotechnologies launch automated mRNA synthesis kits
Codex DNA has launched its BioXp mRNA synthesis kits with CleanCap Reagent, a proprietary mRNA-capping technology from TriLink Biotechnologies, which is part of Maravai Life Sciences. The automation kits allow users to generate large quantities of high-quality, capped mRNA to accelerate the discovery and development of mRNA vaccines and therapeutics. Read More
Turnstone, Moffitt Biologics to advance TIL immunotherapies for solid tumors
Turnstone Biologics has entered into a strategic multiyear research collaboration with the Moffitt Cancer Center for the preclinical development of investigational tumor-infiltrating lymphocyte (TIL) therapies. The partnership will focus on new clinical candidates using Turnstone's next-generation TIL approach in treating multiple solid tumors. Read More
HotSpot Therapeutics secures $100M to advance allosteric platform
HotSpot Therapeutics has closed a $100 million series C financing round to advance its allosteric drug discovery platform to the clinic. This brings the total amount of funding for the company to $190 million. The funds will be used to advance HotSpot's Smart Allostery platform, as well as the company's existing pipeline, according to HotSpot. Read More
Parallel Fluidics secures $1.8M in funding round
Digital microfluidic devices manufacturer Parallel Fluidics has garnered $1.8 million in a new round of financing from a syndicate of investors, founders, and technologists. Read More
Earlham Institute deploys new HiFi platform
The Earlham Institute in Norwich, U.K., has implemented a twin set of Pacific Biosciences' Sequel IIe platform to increase its support for the Earth BioGenome projects. Read More
CRISPR Therapeutics granted FDA RMAT for CTX110 for CD19+ B-cell cancers
CRISPR Therapeutics received the U.S. Food and Drug Administration (FDA) regenerative medicine advanced therapy (RMAT) designation for CTX110, an allogeneic CAR T-cell therapy, for the treatment of relapsed or refractory CD19+ B-cell malignancies. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter